INTELLIA THERAPEUTICS, INC. Business Combination, Contingent Consideration, Liability
INTELLIA THERAPEUTICS, INC. (NTLA) had Business Combination, Contingent Consideration, Liability of $0 as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Balance Sheet › Liabilities
us-gaap:BusinessCombinationContingentConsiderationLiability · last filed 2026-02-26
- 2025-12-31: Business Combination, Contingent Consideration, Liability $0.00.
- 2024-12-31: Business Combination, Contingent Consideration, Liability $0.00.
| Period end | Business Combination, Contingent Consideration, Liability |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-26 |
| 2024-12-31 | $0.00 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |